• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 20
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 20
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    SARS-CoV-2 R&D: Is It Over?

    Sustainability: A New Threat or Opportunity for CDMOs?

    Advanced Therapy Manufacturing

    Advanced Therapy Packaging Trends

    CEO Spotlight: Darren Head
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Piramal Pharma Solutions New API Plant in Canada Now Online

    MG America Appoints Claudio Radossi as President

    Catalent Invests $175M to Expand Mfg. Capabilities at Winchester, KY

    Sartorius Expands Manufacturing Site in Tunisia

    BioMoti Partners with Pharma Company to Develop Ovarian Cancer Treatment
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Piramal Pharma Solutions New API Plant in Canada Now Online

    Selecting a CMO Partner for Sterile Injectable Manufacturing

    Catalent Invests $175M to Expand Mfg. Capabilities at Winchester, KY

    Grand Opening of Kodiak Sciences’ Bioconjugation Facility

    Vertex Expands Cell and Gene Therapy Footprint
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Selecting a CMO Partner for Sterile Injectable Manufacturing

    Royalty Pharma and Jefferies Invest $111M in ApiJect

    Cryoport Acquires Cell&Co BioServices for €6.2M

    Challenges of Developing Large Volume Drug/Device Combination Products for Parenteral SC Delivery

    Yourway Adds Capacity for Controlled Ambient Storage
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Selecting a CMO Partner for Sterile Injectable Manufacturing

    BioMoti Partners with Pharma Company to Develop Ovarian Cancer Treatment

    WCG Appoints Sam Srivastava CEO

    AffyXell Expands Manufacturing Partnership with GenScript ProBio

    ABL and Odimma Therapeutics Enter Development Agreement
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    FDA Inspection Trends Update

    Phase-Appropriate cGMP Considerations for Cell and Gene Therapy

    Sustainability: A New Threat or Opportunity for CDMOs?

    In Pursuit of Sustainability: How the Biopharma Industry Can Contribute

    Conducting Clinical Trials During the Pandemic: What Did We Learn?
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Biosynth Carbosynth

    Vector Partners Limited

    Quotient Sciences

    Qosina

    Baxter BioPharma Solutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Biosynth Carbosynth

    Vector Partners Limited

    Quotient Sciences

    Qosina

    Baxter BioPharma Solutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Podcasts
    • Infographics
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Small Molecule Drug Development Trends

    Lonza’s Robert Beland discusses best practices for manufacturers to shorten development timelines, as well as some of the capabilities at the CDMO's Tampa site.

    Small Molecule Drug Development Trends
    Small Molecule Drug Development Trends
    Robert Beland, Managing Director, Lonza
    Related CONTENT
    • AmbioPharm, Inc.
    • Bora Pharmaceuticals
    • Legacy Pharma Solutions
    • Vio Chemicals
    • Aenova
    Tim Wright, Editor, Contract Pharma05.05.21
    As drug development timelines become shorter for many small molecule drug products, reaching clinic and market faster is growing more important for leaders of small and emerging biotech companies. To meet customer needs, development partners must provide a single source of formulation development, phase-appropriate drug product, complete with integrated packaging and clinical trial logistics.

    Contract Pharma spoke with Robert Beland, Managing Director, Lonza about best practices for pharmaceutical manufacturers to shorten development timelines, as well as some of the capabilities at Lonza’s Tampa site—from micro-dosing to highly potent API drug product development.

    Contract Pharma: What are the biggest challenges that your customers face with advancing their molecules?

    Robert Beland:
    When clients approach us for the first time, they normally fall into two general categories: larger, more established companies or small biopharma companies, including startups. Our larger clients tend to be resource-rich and are typically very prescriptive in their approach thus requiring less problem-solving or program design input from our side. However, most of our clients are smaller and need development partners to progress their molecules.  These customers tend to value more technical input and support. A fair number may not be well prepared with their drug substance, which can delay start dates. Adequate funding is a constant consideration with virtual and small companies, driving them to seek “bare-bones” feasibility studies or first-in-human drug product supply.

    Contract Pharma: What do customers need for the rapid advancement of molecules to phase I and II trials?

    Beland:
    Our clients need an experienced development CDMO to provide a wide array of solutions to their drug development challenges. A case-by-case consultancy approach is often needed to help the client define their objectives and develop a tailored program to meet their technical and commercial goals.

    When speed is of the essence, which is increasingly the norm, and the client is well advanced with their drug substance, we will typically take an API powder-in-capsule (or bottle) approach for phase I supply. One method to accelerate drug development is using a “micro-dosing” approach, which allows for rapid manufacture of drug products in either API-in-capsule or -bottle formats for Phase I studies. Lonza’s Xcelodose micro-dosing systems are utilized for excipient-free capsule or bottle-based drug product, an approach which reduces time to first-in-human trials by up to 45% or 13-17 weeks vs. conventional routes. The Tampa team has industry-leading experience in micro-dosing and have developed best practices based on the work with more than 200 APIs.

    If the customer needs drug substance and/or issues with sufficient solubility for early-stage work, we can take our client quicker to the clinic with our SimpliFIH Solutions offering. This service was developed for speed, combining drug substance and drug product development and supply for phase I in the fastest way possible. We recently announced an expansion in our solid form services component of this service package which is typically required to identify the most progressible drug substance form.

    Contract Pharma: What priorities did you set for Tampa site and team upon your arrival?

    Beland:
    The priorities were relatively simple. First, we needed to transform the site from an entrepreneurial company and quickly integrate it into Lonza to benefit from being part of a larger CDMO with a wide service range and a solid global reputation. After that, we narrowed our focus on oral solid dosage forms as a service offering and worked at becoming “best in class” for this offering. We overlaid the needs for small and emerging companies to determine what specific service refinements were needed to meet their expectations. Last, we performed a gap analysis on our resources to make sure we had the talent and tools in place to fulfill our ambitions. The journey continues of course, and constant improvement based on customer feedback is always our focus.

    Contract Pharma: What investments have been made and why?

    Beland
    : In under four years, we invested more than $20 million in Tampa to upgrade the facilities, increase capacity, and add the capability to handle HPAPI compounds in a scalable way from product development to GMP manufacturing and packaging. Our product development capabilities have been expanded along with four new suites for clinical manufacturing for a total of 17 manufacturing suites. We increased the size of our suites, created more suites designed ‘for purpose’, added three HPAPI dedicated suites (one development, two GMP), and two low humidity suites. Oral solid dose and dry powder inhaler (DPI) capabilities have been increased, so we can now effectively scale DPI formulations from small scale Xcelodose-based encapsulation to commercial scale with a Harro Hoefliger Modu-C unit. 

    Within the Lonza site network, we continue to focus on and implement consistent approaches to project management, quality systems, data management and more to fully leverage our overall customer support capabilities. Another objective is matching equipment trains through the Lonza network to offer redundancy and seamless transitions for clients.

    Contract Pharma: How does the Tampa site support global clinical trials?

    Beland:
    We can support the development of almost any oral solid dosage form as well as almost any global clinical trial configuration. Drug product development and manufacturing is integrated with our clinical packaging services in Tampa and at our sister facility in Burton-upon-Trent, UK. I consider this a core strength of our clinical drug product services—primary and secondary packaging, labeling, kitting, global distribution, returns and destruction. All required serialization is in place, and we support direct-to-patient models as well, which are becoming more prevalent. Our global network of depots and carriers is designed to ensure the release and distribution of drug product virtually anywhere in the world. Last year, we distributed clinical materials to more than 30 countries.

    Contract Pharma: How does the Tampa site interact with the broader network in advancing client molecules?

    Beland:
    It all starts at the proposal level from the first client interaction. Our Technical Sales team identifies the technologies and services that customers require, then determines the best combination of sites needed for each client. Sites span from drug substance in Nansha, CN and Visp, CH to micronization in Monteggio, CH and Quakertown, PA to bioavailability enhancement and drug product services in Bend, OR to drug product development and clinical services in Tampa. Once the right combination of sites is established, the project is managed by our supply chain and program management team with a single team lead to make the process as seamless as possible for the customer.

    Contract Pharma: What’s next?

    Beland:
    We are looking at broadening our range of technologies with a first step in inhalation analytical capabilities by the end of this year to complement our existing development and manufacturing offering. Over the coming years, we will continue expanding Lonza-Tampa’s capabilities and capacity in line with our customers’ needs. 
    Suggested For You
    AmbioPharm, Inc. AmbioPharm, Inc.
    Bora Pharmaceuticals Bora Pharmaceuticals
    Legacy Pharma Solutions Legacy Pharma Solutions
    Vio Chemicals Vio Chemicals
    Aenova Aenova
    ViscoTec America Inc. ViscoTec America Inc.
    Experic Experic
    MedPharm MedPharm
    PCI Pharma Services PCI Pharma Services
    Lonza Further Invests in Drug Product Manufacturing Capabilities Lonza Further Invests in Drug Product Manufacturing Capabilities
    pHOXBIO Unveils Trial Results from COVID Prophylactic Nasal Spray pHOXBIO Unveils Trial Results from COVID Prophylactic Nasal Spray
    Immunic Inc. Signs In-License Agreement with University Medical Center Goettingen, Germany Immunic Inc. Signs In-License Agreement with University Medical Center Goettingen, Germany
    First Patient is Dosed with Triumvira First Patient is Dosed with Triumvira's Investigational TAC-T Cell Adoptive Immunotherapy
    Naobios to Manufacture FluGen’s M2SR Flu Vax Candidate  Naobios to Manufacture FluGen’s M2SR Flu Vax Candidate
    Clean Cells Expands Bioproduction Capabilities Clean Cells Expands Bioproduction Capabilities

    Related Content

    • AmbioPharm, Inc.

      ...
      Denise Karounos, Sr Marketing Manager 04.05.22

    • Bora Pharmaceuticals

      Bora Pharmaceuticals

      ...
      Lonnie Barish, VP, Business Development 03.09.22

    • Legacy Pharma Solutions

      Legacy Pharma Solutions

      ...
      Nathan Bender, Director, Sales & Marketing 12.07.21


    • Vio Chemicals

      ...
      Ioanna Kazantzidou, Marketing Communications Officer 12.07.21

    • Aenova

      Aenova

      ...
      Susanne Knabe, Head of Communication & PR 11.30.21

      Trending
      • Cellipont Bioservices Expands Cell Therapy Facility | Contract Pharma
      • Biopharma Manufacturing Facility Construction | Contract Pharma
      • Next-Gen Lab Services | Contract Pharma
      • Pharma Development & Manufacturing Trends | Contract Pharma
      • Reviving Local Production Of Antibiotic Powders | Contract Pharma
      Breaking News
      • Piramal Pharma Solutions New API Plant in Canada Now Online
      • MG America Appoints Claudio Radossi as President
      • Catalent Invests $175M to Expand Mfg. Capabilities at Winchester, KY
      • Sartorius Expands Manufacturing Site in Tunisia
      • BioMoti Partners with Pharma Company to Develop Ovarian Cancer Treatment
      View Breaking News >
      CURRENT ISSUE

      May 2022

      • Sustainability and the Biopharma Industry
      • Contract Manufacturing During COVID
      • Orphan Drugs in the United States
      • CEO Spotlight: Peter DeYoung
      • CEO Spotlight: Darren Head
      • Advanced Therapy Packaging Trends
      • Advanced Therapy Manufacturing
      • Sustainability: A New Threat or Opportunity for CDMOs?
      • SARS-CoV-2 R&D

      Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
      You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

      • About Us
      • Privacy Policy
      • Terms And Conditions
      • Contact Us

      follow us

      Subscribe
      Nutraceuticals World

      Latest Breaking News From Nutraceuticals World

      GOED Creates Infographic Highlighting Omega-3 Health Claims Approved in Europe
      Kyowa Hakko Appoints Dr. Colin Hill to Immuse Scientific Advisory Board
      Expert Consensus Statement: Diet is Best Primary Intervention to Achieve Diabetes Remission
      Coatings World

      Latest Breaking News From Coatings World

      What Are You Reading?
      Teknos Receives EcoVadis Gold Medal for Sustainability Performance
      AkzoNobel and Partners Team Up to Hack Carbon Reduction Challenges
      Medical Product Outsourcing

      Latest Breaking News From Medical Product Outsourcing

      MPO's Most-Read Stories This Week—May 21
      Iterative Scopes Expands its Senior Leadership Team
      Viz.ai Raises $100 Million in Series D Funding
      Contract Pharma

      Latest Breaking News From Contract Pharma

      Piramal Pharma Solutions New API Plant in Canada Now Online
      MG America Appoints Claudio Radossi as President
      Catalent Invests $175M to Expand Mfg. Capabilities at Winchester, KY
      Beauty Packaging

      Latest Breaking News From Beauty Packaging

      Authentic Beauty Concept Launches Second-Generation ‘Refill Bar’
      HASK Beauty Enters Exclusive Partnership with Amazon
      Garance Doré Launches Made in France Skincare Line
      Happi

      Latest Breaking News From Happi

      P&G Closes HQ Due To Security Threat, Launches New Hair Care Line
      SPF Setting Spray, Lip Contour and Knotless Braids Are Hot Trends: Spate
      Nutrafol Launches Collagen Infusion
      Ink World

      Latest Breaking News From Ink World

      Weekly Recap: Zeller+Gmelin, Sun Chemical and Kornit Top This Week’s News
      Nazdar Celebrates 100 Years with a New Look
      hubergroup Chemicals Exhibits at Paint India for First Time
      Label & Narrow Web

      Latest Breaking News From Label & Narrow Web

      Brook + Whittle's new acquisition, SunDance goes to HP and more
      Specialty announces move to new facility
      Mark Andy hosts dealer's open house in Warsaw
      Nonwovens Industry

      Latest Breaking News From Nonwovens Industry

      Weekly Recap: Kimberly-Clark to Expand Diaper, Wipes Production in Brazil; The Honest Company to Sell Diapers, Wipes at Walmart & More
      3M to Expand in Nebraska
      Nicely Offers Nonwoven Slitters, Winders
      Orthopedic Design & Technology

      Latest Breaking News From Orthopedic Design & Technology

      ODT's Most Read Stories This Week—May 21
      FDA Clears Anika Therapeutics' X-Twist Knotless Fixation System
      Paragon 28 Rolls Out TenoTac 2.0 Hammertoe and Soft Tissue Repair
      Printed Electronics Now

      Latest Breaking News From Printed Electronics Now

      Weekly Recap: Graphene Flagship, Japan Display and LG Display Top This Week’s Stories
      Evonik Launches New Processing Aids for PV Wafer Cutting
      NREL Creates Highest Efficiency 1-Sun Solar Cell

      Copyright © 2022 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

      AD BLOCKER DETECTED

      Our website is made possible by displaying online advertisements to our visitors.
      Please consider supporting us by disabling your ad blocker.


      FREE SUBSCRIPTION Already a subscriber? Login